

## Literaturverzeichnis

Hamburger Ärzteblatt 7/8 | 2023

Seite 1

Weidestr. 122 b  
22083 Hamburg  
Redaktion

E-Mail: [verlag@aekhh.de](mailto:verlag@aekhh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 12 – 16: Diabetes mellitus Typ 2 – Gewichtsreduktion als co-primäres Therapieziel.

Von Dr. Anne Lautenbach, Dr. Pia Roser, Dr. Tobias Kantowski, Dr. Clarissa Schulze zur Wiesch, Prof. Dr. Jens Aberle

1. Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2022; 45: 2753–2786. doi:10.2337/DCI22-0034.
2. Wall JR, Pyke DA, Oakley WG. Effect of Carbohydrate Restriction in Obese Diabetics: Relationship of Control to Weight Loss. *Br Med J* 1973; 1: 577–578. doi:10.1136/BMJ.1.5853.577.
3. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* 2018; 391: 541–551. doi:10.1016/S0140-6736(17)33102-1.
4. Lean MEJ, Leslie WS, Barnes AC et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol* 2019; 7: 344–355. doi:10.1016/S2213-8587(19)30068-3.
5. Taylor R, Barnes AC, Irvine KM et al. Diabetes remission by weight loss in „normal“ weight people with type 2 diabetes: the ReTUNE study. <https://www.abstractsonline.com/pp8/#!/10613/presentation/308>; Stand: 30.01.2023
6. Davies M, Færch L, Jeppesen OK et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet* 2021; 397: 971–984. doi:10.1016/S0140-6736(21)00213-0.
7. Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med* 2021; 384: 989–1002. doi:10.1056/NEJMOA2032183/SUPPL\_FILE/NEJMOA2032183\_DATA-SHARING.PDF
8. Bakker W, Imbernon M, Salinas CG et al. Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. *Cell Rep* 2022; 41: 111698. doi:10.1016/J.CELREP.2022.111698.
9. Imbernon M, Saponaro C, Helms HCC et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. *Cell Metab* 2022; 34: 1054-1063.e7. doi:10.1016/j.cmet.2022.06.002.
10. Frías JP, Auerbach P, Bajaj HS et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol* 2021; 9: 563–574. doi:10.1016/S2213-8587(21)00174-1.
11. Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med* 2016; 375: 1834–1844. doi:10.1056/NEJMOA1607141/SUPPL\_FILE/NEJMOA1607141\_DISCLOSURES.PDF
12. Frías JP, Davies MJ, Rosenstock J et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med* 2021; 385: 503–515. doi:10.1056/NEJMOA2107519/SUPPL\_FILE/NEJMOA2107519\_DATA-SHARING.PDF
13. Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. *Front Endocrinol (Lausanne)* 2022; 13: 2570. doi:10.3389/FENDO.2022.1004044/BIBTEX.
14. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. *Cardiovasc Diabetol* 2022; 21: 1–16. doi:10.1186/S12933-022-01604-7/TABLES/3.
15. Zhang C, Vincelette LK, Reimann F et al. A brainstem circuit for nausea suppression. *Cell Rep* 2022; 39. doi:10.1016/J.CELREP.2022.110953
16. Frias JP, Bonora E, Ruiz LN et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). *Diabetes Care* 2021; 44: 765–773. doi:10.2337/DC20-1473.

## Literaturverzeichnis

Hamburger Ärzteblatt 7/8 | 2023

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekhh.de](mailto:verlag@aekhh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

17. Van J, Frias JP, Bonora E et al. Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. *Diabetes Ther* 2021; 12: 2783–2794. doi:10.1007/S13300-021-01140-9.
18. Marso SP, Daniels GH, Frandsen KB et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016; 375: 311–322. doi:10.1056/NEJMoa1603827
19. Capehorn MS, Catarig AM, Furberg JK et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). *Diabetes Metab* 2020; 46: 100–109. doi:10.1016/J.DIABET.2019.101117.
20. Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. *JAMA* 2022; 327: 138–150. doi:10.1001/JAMA.2021.23619.
21. Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. *Drugs* 2019; 79: 219–230. doi:10.1007/S40265-019-1057-0.
22. Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? *Trends Endocrinol Metab* 2020; 31: 410–421. doi:10.1016/J.TEM.2020.02.006.
23. Mingrone G, Panunzi S, De Gaetano A et al. Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. *N Engl J Med* 2012; 366: 1577–1585. doi:10.1056/NEJMoa1200111.
24. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006; 444: 840–846. doi:10.1038/NATURE05482.
25. Lingvay I, Sumithran P, Cohen R V et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet (London, England)* 2022; 399: 394–405. doi:10.1016/S0140-6736(21)01919-X.
26. Ahlqvist E, Storm P, Käräjämäki A et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* 2018; 6: 361–369. doi:10.1016/S2213-8587(18)30051-2.
27. Tanabe H, Masuzaki H, Shimabukuro M. Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective. *Diabetes Res Clin Pract* 2021; 180. doi:10.1016/J.DIABRES.2021.109067.
28. Raverdy V, Cohen RV, Caiazzo R et al. Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study. *Lancet Diabetes Endocrinol* 2022; 10: 167–176. doi:10.1016/S2213-8587(22)00005-5.

Angaben zu möglichen Interessenkonflikten: vorhanden.

Dr. Anne Lautenbach: Honorare für Vortrags- und Beratertätigkeit von Novo Nordisk, Boehringer Ingelheim und Lilly Deutschland

Dr. Pia Roser: Honorare für Vortrags- und Beratertätigkeit von Bayer und Boehringer Ingelheim

Prof. Dr. Jens Aberle: Honorare für Vortrags- und Beratertätigkeit von Astra Zeneca, Boehringer Ingelheim, Lilly Deutschland und Novo Nordisk

## Literaturverzeichnis

Hamburger Ärzteblatt 7/8 | 2023

Seite 3

Weidestr. 122 b  
22083 Hamburg  
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 32 – 34: ECMO-Therapien: Indikationen und Komplikationen.

*Von Dr. Josephine Braunsteiner, Dr. Gerold Söffker, Dr. Benedikt Schrage, PD Dr. Alexander Bernhardt, Prof. Dr. Stefan Blankenberg, Prof. Dr. Hermann Reichenspurner, Prof. Dr. Stefan Kluge*

1. Becher PM, Schrage B, Sinning CR, Schmack B, Fluschnik N, Schwarzl M, et al. Venoarterial Extracorporeal Membrane Oxygenation for Cardiopulmonary Support. *Circulation*. 2018;138(20):2298-300.
2. Wilson-Smith AR, Bogdanova Y, Roydhouse S, Phan K, Tian DH, Yan TD, et al. Outcomes of venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock: systematic review and meta-analysis. *Ann Cardiothorac Surg*. 2019;8(1):1-8.
3. Bernhardt AM, Schrage B, Schroeder I, Trummer G, Westermann D, Reichenspurner H. Extracorporeal Membrane Oxygenation. *Dtsch Arztebl Int*. 2022.
4. Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M et al. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. *Circulation*. 2023;147(6):454-64.
5. Yannopoulos D, Bartos J, Raveendran G, Walser E, Connett J, Murray TA et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. *Lancet (London, England)*. 2020;396(10265):1807-16.
6. Suverein MM, Delnoij TSR, Lorusso R, Brandon Bravo Bruinsma GJ, Otterspoor L, Elzo Kraemer CV et al. Early Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest. *New England Journal of Medicine*. 2023;388(4):299-309.
7. Belohlavek J, Smalcova J, Rob D, Franek O, Smid O, Pokorna M et al. Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *Jama*. 2022;327(8):737-47.
8. S3-Leitlinie Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz. 2017(1. Auflage).
9. Tonna JE, Abrams D, Brodie D, Greenwood JC, Rubio Mateo-Sidron JA, Usman A et al. Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO). *Asaio j*. 2021;67(6):601-10.
10. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. *Lancet*. 2009;374(9698):1351-63.
11. Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. *New England Journal of Medicine*. 2018;378(21):1965-75.
12. Combes A, Peek GJ, Hajage D, Hardy P, Abrams D, Schmidt M et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. *Intensive care medicine*. 2020;46(11):2048-57.
13. Whebell S, Zhang J, Lewis R, Berry M, Ledot S, Retter A et al. Survival benefit of extracorporeal membrane oxygenation in severe COVID-19: a multi-centre-matched cohort study. *Intensive Care Medicine*. 2022;48(4):467-78.
14. Shaefi S, Brenner SK, Gupta S, O'Gara BP, Krajewski ML, Charytan DM et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. *Intensive Care Med*. 2021;47(2):208-21.
15. Herrmann J, Lotz C, Karagiannidis C, Weber-Carstens S, Kluge S, Putensen C et al. Key characteristics impacting survival of COVID-19 extracorporeal membrane oxygenation. *Critical Care*. 2022;26(1):190.

## Literaturverzeichnis

Hamburger Ärzteblatt 7/8 | 2023

Seite 4

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekhh.de](mailto:verlag@aekhh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

16. Lebreton G, Schmidt M, Ponnaiah M, Folliguet T, Para M, Guihaire J et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. *Lancet Respir Med.* 2021;9(8):851-62.
17. Friedrichson B, Mutlak H, Zacharowski K, Piekarski F. Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs. *Crit Care.* 2021;25(1):38.
18. Braune S, Sieweke A, Jarczak D, Kluge S. Extrakorporale Verfahren zur Lungenunterstützung. *Medizinische Klinik - Intensivmedizin und Notfallmedizin.* 2017;112(5):426-36.
19. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. *Am J Respir Crit Care Med.* 2015;191(8):894-901.
20. ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support Extracorporeal Life Support Organization. 2017.
21. Kluge S, Sensen B, Braune S. [Extracorporeal Lung Support in Patients with ARDS]. *Deutsche medizinische Wochenschrift (1946).* 2017;142(2):88-95.
22. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J et al. Complications of Extracorporeal Membrane Oxygenation for Treatment of Cardiogenic Shock and Cardiac Arrest: A Meta-Analysis of 1,866 Adult Patients. *The Annals of Thoracic Surgery.* 2014;97(2):610-6.

Angaben zu möglichen Interessenkonflikten: vorhanden:

Prof. Dr. Kluge: Vortrags- und Beraterhonorare von Fresenius Medical Care

### S. 35: Bilder aus der klinischen Medizin: Paget-von-Schroetter-Syndrom.

Von Dr. Denis Ueberschär, MBA, Dr. Murat Dogan

1. Bürger T, Stegemann E et al. V. subclavia Thrombose bei Thoracic-inlet-Syndrom. *Gefäßchirurgie* 08/2016.
2. Chun TT, O'Connell JB et al. Preoperative thrombolysis is associated with improved vein patency and functional outcomes after first rib resection in acute Paget-Schroetter syndrome *J Vasc Surg* 2022 Sep;76(3):806-813.e1.
3. de Leon RA, Chang DC, Hassoun HAT et al. Multiple treatment algorithms for successful outcomes in venous thoracic outlet syndrome. *Surgery* 2009;145:500-507.
4. Doyle A, Wolford H et al. Management of effort thrombosis of the subclavian vein: today's treatment *Ann Vasc Surg* 2007 Nov;21(6):723-9.
5. Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome treated with thrombolytics and immediate surgery. *J Vasc Surg* 2007;45:328-334.
6. Thompson JF, Winterborn RJ, Bays S et al. Venous thoracic outlet compression and the Paget-Schroetter syndrome: a review and recommendations for management. *Cardiovasc Intervent Radiol* 2011;34:903-910.

## Literaturverzeichnis

Hamburger Ärzteblatt 7/8 | 2023

Seite 5

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekeh.de](mailto:verlag@aekeh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 36 – 37: Der besondere Fall: Durchblutungsstörungen im Darm.

*Von Ann-Katrin von Schassen, Dr. Lia Conradt, Dr. Konstanze Holl-Ulrich, Inga Braun*

1. Genta RM, Haggitt RC. Idiopathic myointimal hyperplasia of mesenteric veins. *Gastroenterology*. 1991 Aug;101(2):533-9.
2. Abu-Alfa AK, Ayer U, West AB. Mucosal biopsy findings and venous abnormalities in idiopathic myointimal hyperplasia of the mesenteric veins. *Am J Surg Pathol*. 1996 Oct;20(10):1271-8.
3. Song SJ, Shroff SG. Idiopathic Myointimal Hyperplasia of Mesenteric Veins of the Ileum and Colon in a Patient with Crohn's Disease: A Case Report and Brief Review of the Literature. *Case Rep Pathol*. 2017;6793031.
4. Martin FC, Yang LS, Fehily SR, D'Souza B, Lim A, McKelvie PA. Idiopathic myointimal hyperplasia of the mesenteric veins: Case report and review of the literature *JGH Open*. 2019 Dec 27;4(3):345-350.
5. Li H, Shu H, Zhang H, Cui M, Gao Y, Tian F. Idiopathic Myointimal Hyperplasia of the Mesenteric Veins: A Case Report and Scoping Review of Previously Reported Cases From Clinical Features to Treatment. *Front Med (Lausanne)*. 2022 Apr 13;9:855335.

Angaben zu möglichen Interessenkonflikten: keine

### S. 38: Die vom Weg Abgekommene

*Von Dr. Jürgen Madert*

1. European Route of Industrial Heritage. ZUR INDUSTRIEGESCHICHTE VON FRANKREICH. <https://www.erih.de/wie-alles-begann/industriegeschichte-europaeischer-laender/erih-europaeische-route-der-industriekultur-industriegeschichte-frankreich>
2. Fath R. La Traviata. Reclams Opernführer. 41 Auflage 2017; Philip Reclam Verlag
3. König M. Drei Frauen, ein Mythos: Wie Alphonsine Plessis zu Violetta Valéry wurde. *Opernhausblog* 24.09.2017
4. Oury M. Geschichte der Tuberkulose in Illustrierte Geschichte der Medizin, Band 5: 2735-2755. Andreas & Andreas Verlagsbuchhandel, Salzburg 1986.
5. Peters PM. Paris-Montmartre, Marie Duplessis – von Fantasien geformt, eine Zueignung, 19.09.2020; IOCO – Kultur im Netz. [www.ioco.de/2020/09/19/paris-montmartre-marie-duplessis-von-fantasien-geformt-eine-zueignung-19-09-2020/](http://www.ioco.de/2020/09/19/paris-montmartre-marie-duplessis-von-fantasien-geformt-eine-zueignung-19-09-2020/)
6. Robert-Koch-Institut. RKI-Ratgeber -Tuberkulose 2013.
7. Türk EE. Tuberkulose. *Rechtsmedizin*, Springer 2006;16:143-150.